TenNor Therapeutics (Suzhou) Ltd. - B - H Shares Stock: price and insider trades · Hong Kong
HK·Mcap HK$5.9B
TenNor Therapeutics (Suzhou) Ltd. - B - H Shares: what insiders have been doing
Insider filings for TenNor Therapeutics (Suzhou) Ltd. - B - H Shares are scarce in the HKEX feed, the latest one published on 8 June 2026. This page will fill in as new trades are disclosed. Every figure here comes from the filings published by HKEX and describes the past, not future prices; it is not investment advice.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Financial data
as of FY 2025FY ended December 2025 · cache
HK$112.10
Analyst consensus
Income statement
EBITDA-HK$150.2M
Net income-HK$153.2M0.0% margin
Valuation
P/Book7.7x
Balance sheet & cash
Market capHK$5.9B
Total debtHK$28.7M
Free Cash Flow-HK$87.6M
Debt / Equity10%
Profitability & ownership
ROA-41.4%
% insiders55.4%
% institutions24.8%
Last declaration on 8 June 2026
About TenNor Therapeutics (Suzhou) Ltd. - B - H Shares
TenNor Therapeutics (Suzhou) Ltd. is a biopharmaceutical company focused on developing innovative treatments for serious diseases. It specializes in the research and commercialization of targeted therapies.